Directorate Change

RNS Number : 1204S

Circassia Pharmaceuticals Plc

16 December 2016

 

Circassia Pharmaceuticals plc

Non-Executive Director Retirement

Oxford, UK - 16 December 2016: Circassia Pharmaceuticals plc ("Circassia" or "the Company"; LSE: CIR), a specialty biopharmaceutical company focused on allergy and asthma, today announces the retirement of Cathrin Petty from its Board, following nearly seven years as a Non-Executive Director. 

Dr Francesco Granata, Circassia's Chairman, commented: "On behalf of the Board, I would like to thank Cathrin for her significant contribution to the Company over many years, and we wish her well in her new role as Head of European Healthcare at CVC Capital Partners."

Commenting on her retirement, Cathrin Petty said: "I firmly believe that Circassia is well positioned to achieve its ambition to become a self-sustaining, world-class specialty biopharmaceutical company.  Unfortunately, the time commitments of my new role preclude me from contributing further as a Director, but I will continue to follow Circassia's progress keenly."

-Ends-

For further information, please contact:

Circassia Steve Harris, Chief Executive Officer Julien Cotta, Chief Financial Officer Rob Budge, Corporate Communications	Tel: [phone]
FTI Consulting Ben Atwell / Simon Conway / Mo Noonan	Tel: [phone]

 

END

 

 

BOAGGGPCPUPQGCQ